Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Concise verdict

    GΓ©rard 2013 is a rigorous, well-referenced narrative review summarizing known microbial pathways that convert cholesterol to coprostanol and generate >20 secondary bile acids via deconjugation (BSHs), HSDH-mediated oxidation/epimerization, 7Ξ±-dehydroxylation (bai operon), esterification and desulfatation β€” it correctly highlights mechanistic gaps (few cultured/annotated genes for cholesterol reduction) and translational uncertainty about health impacts, and it usefully frames priorities: gene discovery, gnotobiotic models, and metabolomics-driven causal studies




     Long Explanation


    Visual review β€” GΓ©rard (2013): Metabolism of cholesterol & bile acids by gut microbiota

    One-line summary
    A compact, authoritative narrative review describing microbial conversions of cholesterol (to coprostanol) and primary bile acids (multiple secondary bile acids) and mapping the major enzymes, taxa, and open knowledge gaps for mechanistic and translational work

    Figure: GΓ©rard 2013 lists these seven major transformations and discusses taxa/enzymes for each (BSHs, HSDHs, bai operon), noting multiple intermediate metabolites and >20 secondary bile acids in feces

    Note: counts are a synthesis of genera named in Table 1 of the paper (Bacteroides, Bifidobacterium, Clostridium, Lactobacillus, Listeria for deconjugation; broader list for oxidation/epimerization; Clostridium/Eubacterium for 7Ξ±-dehydroxylation)

    Critical assessment (evidence-focused)

    • Strengths: authoritative synthesis of decades of biochemical and culture-based work; clear mechanistic maps (cholesterolβ†’coprostanol routes; bai operon detailed in Clostridium), practical translational questions flagged (need for gene identification, gnotobiotic models)
    • Limitations / blindspots:
      • Narrative review β€” selective coverage risk. The review relies heavily on culture-based enzymology; modern metagenomic/metatranscriptomic evidence (post-2013) expands gene catalogs and should be integrated to confirm activity in situ
      • Insufficient genome-level annotation for cholesterol-reducing enzymes: GΓ©rard correctly notes few isolates & unknown genes for cholesterolβ†’coprostanol β€” this remains a critical experimental gap (identification of isomerases/3Ξ²-HSD/other catalytic genes)
      • Translational assertions are cautious but empirical causal links remain sparse: animal studies produce mixed results (hypocholesterolemic effects in rabbits; null in mice/hens). GΓ©rard properly warns about species differences and the need for controlled gnotobiotic experiments
    • Methodological caveats to watch: many primary studies are biochemical assays or small animal trials; human observational associations (coprostanol:cholesterol fecal ratios vs serum cholesterol) are correlational and confounded by diet, transit time and host genetics

    What would change the conclusions?

    1. Identification of ubiquitous, high-expression genes in human gut metagenomes encoding cholesterol reductases that are not linked to coprostanol formation would challenge the enzyme scarcity claim.
    2. Robust human randomized interventions that alter cholesterol-reducing taxa (or transfer of defined cholesterol-reducing consortia) without changing serum cholesterol would weaken the causal link implied.
    3. Conversely, genome-resolved identification of cholesterol->coprostanol genes whose manipulation alters host cholesterol would strengthen the review's translational argument.

    Key sources used in this critique



    Feedback:    

    Updated: March 18, 2026

     BGPT Paper Review


    Study Novelty

    60%

    The review compiles well-established enzymology and culture-based discoveries up to 2013 (cholesterol→coprostanol and bile-acid conversions). It is moderately novel in synthesizing cholesterol reduction alongside detailed bile-acid pathways and in calling for genome-level discovery, but it does not present new primary data.


    Scientific Quality

    90%

    High-quality narrative synthesis: well-referenced (50 refs), accurate mechanistic descriptions, clear limitations section. No obvious methodological flaws for a review; quality limited by being pre-metagenomics era for some claims and by narrative selection bias inherent to non-systematic reviews.


    Study Generality

    70%

    Content applies broadly across human gut microbiology and sterol metabolism; covers many taxa and reactions, and links to host diseases, but some experimental results are species-specific and translation requires caution.


    Study Usefulness

    80%

    Very useful for microbiome researchers, enzymologists, and translational scientists designing gene-discovery and gnotobiotic experiments; highlights tractable research directions (bacterial isolates, bai operon, BSH/HSDH characterization).


    Study Reproducibility

    40%

    As a narrative review, reproducibility depends on primary studies; many cited works are culture/biochemistry studies (reproducible in principle) but raw data and genome-level annotations for cholesterol reducers are absent, hampering reproducible functional assignment in metagenomes.


    Explanatory Depth

    70%

    Good mechanistic coverage of enzymatic steps (oxidation/epimerization, CoA-ligation & bai operon steps) and biochemical intermediates, but lacks genome-resolved mapping of cholesterol-reduction enzymes and in vivo host–microbe mechanistic pathways that would elevate explanatory depth.


    🎁 Authors: Collect 169 Free Science Tokens (β‰ˆ $16.9 USD)

    Claim My Author Tokens

    Use for 42 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $16.9 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Searching human gut metagenomes for candidate cholesterol-reductase homologs by protein HMM scanning and differential abundance between high/low coprostanol fecal converters (using assembled metagenomes and gene catalogs from cited studies).



     Hypothesis Graveyard


    Coprostanol formation is entirely a host-independent, constitutive process: falsified because conversion efficiency varies bimodally across humans and requires bacterial load thresholds and specific taxa presence/abundance (<-> observed interindividual variability)


    Single universal enzyme performs both cholesterol direct-reduction and indirect (4-cholesten-3-one) pathways: unlikely because intermediates (coprostanone, 4-cholesten-3-one) and isolates show evidence of multi-step enzymatic cascades and distinct enzyme activities in different taxa, suggesting multi-enzyme pathways rather than a single enzyme.

     Science Art


    Paper Review: Metabolism of Cholesterol and Bile Acids by the Gut Microbiota Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending